P
ProHub
English 简体中文 繁體中文
BCG Medium Outsourcing Cost Reduction Operations

Biopharma Outsourcing

#Pharmaceuticals #Biopharma
ProHub Comment

This case requires structured cost-benefit analysis combining variable and fixed cost modeling with operational and regulatory risk assessment. The candidate must navigate the tension between significant cost savings ($8.875M) and non-financial risks (regulatory compliance, quality control, frozen shipment logistics), demonstrating both analytical rigor and strategic thinking.

Estimated Time 15 minutes
Difficulty Medium
Source Wharton
50 / 100
The client, Genome Bio, is a national biopharma manufacturer of the largest life-saving medicines for diseases and manufactures bio-materials in the USA. Due to the COVID pandemic, the costs of manufacturing these materials has significantly shot up and the client has been considering establishing manufacturing facilities in Mexico. Should the client outsource the supply of the biomaterial to Mexico facilities?

Clarifying Information

  1. Objective: To reduce costs of sourcing of the biomaterial and evaluate other benefits of establishing an alternate supply chain
  2. Business: The client owns and operates the facilities for biomaterial production and has a network of biomaterial production
  3. Customers: The biomaterials are manufactured and then sent distributed all over the US